Journal article
Kelly A. S. da Costa, J. M. D. Del Rosario, Matteo Ferrari, Sneha Vishwanath, B. Asbach, R. Kinsley, Ralf Wagner, J. Heeney, G. Carnell, Nigel James Temperton
Vaccines, 2022
Vaccines, 2022
Semantic Scholar
DOI
PubMedCentral
PubMed
Cite
Cite
APA
Click to copy
da Costa, K. A. S., Rosario, J. M. D. D., Ferrari, M., Vishwanath, S., Asbach, B., Kinsley, R., … Temperton, N. J. (2022). Influenza A (N1-N9) and Influenza B (B/Victoria and B/Yamagata) Neuraminidase Pseudotypes as Tools for Pandemic Preparedness and Improved Influenza Vaccine Design. Vaccines.
Chicago/Turabian
Click to copy
Costa, Kelly A. S. da, J. M. D. Del Rosario, Matteo Ferrari, Sneha Vishwanath, B. Asbach, R. Kinsley, Ralf Wagner, J. Heeney, G. Carnell, and Nigel James Temperton. “Influenza A (N1-N9) and Influenza B (B/Victoria and B/Yamagata) Neuraminidase Pseudotypes as Tools for Pandemic Preparedness and Improved Influenza Vaccine Design.” Vaccines (2022).
MLA
Click to copy
da Costa, Kelly A. S., et al. “Influenza A (N1-N9) and Influenza B (B/Victoria and B/Yamagata) Neuraminidase Pseudotypes as Tools for Pandemic Preparedness and Improved Influenza Vaccine Design.” Vaccines, 2022.
BibTeX Click to copy
@article{kelly2022a,
title = {Influenza A (N1-N9) and Influenza B (B/Victoria and B/Yamagata) Neuraminidase Pseudotypes as Tools for Pandemic Preparedness and Improved Influenza Vaccine Design},
year = {2022},
journal = {Vaccines},
author = {da Costa, Kelly A. S. and Rosario, J. M. D. Del and Ferrari, Matteo and Vishwanath, Sneha and Asbach, B. and Kinsley, R. and Wagner, Ralf and Heeney, J. and Carnell, G. and Temperton, Nigel James}
}
Abstract
To better understand how inhibition of the influenza neuraminidase (NA) protein contributes to protection against influenza, we produced lentiviral vectors pseudotyped with an avian H11 hemagglutinin (HA) and the NA of all influenza A (N1–N9) subtypes and influenza B (B/Victoria and B/Yamagata). These NA viral pseudotypes (PV) possess stable NA activity and can be utilized as target antigens in in vitro assays to assess vaccine immunogenicity. Employing these NA PV, we developed an enzyme-linked lectin assay (pELLA) for routine serology to measure neuraminidase inhibition (NI) titers of reference antisera, monoclonal antibodies and post-vaccination sera with various influenza antigens. We also show that the pELLA is more sensitive than the commercially available NA-Fluor™ in detecting NA inhibition in these samples. Our studies may lead to establishing the protective NA titer that contributes to NA-based immunity. This will aid in the design of superior, longer lasting and more broadly protective vaccines that can be employed together with HA-targeted vaccines in a pre-pandemic approach.
